The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center

Objective: To determine the influence of the Oncotype Dx assay on the treatment of patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative, axillary lymph node-negative or micrometastatic carcinoma of the breast in a single cancer center. In addition,...

Full description

Bibliographic Details
Main Authors:	Stephane Thibodeau, Ioannis A. Voutsadakis
Format:	Article
Language:	English
Published:	Galenos Publishing House 2019-07-01
Series:	European Journal of Breast Health
Subjects:	oncotype dx breast cancer recurrence risk prediction retrospective
Online Access:	http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/the-oncotype-dx-assay-in-er-positive-her2-negative/41982

Similar Items

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
by: T. M. Aherne, et al.
Published: (2020-04-01)

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01)

The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
by: Atilla Soran, et al.
Published: (2020-04-01)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
by: Çağlar Ünal, et al.
Published: (2023-06-01)

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx
by: Michał Jarząb, et al.
Published: (2024-10-01)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
by: Michael Crager, et al.
Published: (2022-11-01)

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
by: John Loggie, et al.
Published: (2024-06-01)

Correlation analysis between mammography features of early-stage invasive breast ductal carcinoma with positive ER, negative HER2, negative lymph node and Oncotype DX21 gene assay results
by: WANG Ting , LIU Zhuang , GONG Jing , JIANG Lin , SHEN Xigang , GU Yajia
Published: (2021-06-01)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019-05-01)

Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey
by: Vahit Özmen, et al.
Published: (2016-07-01)

Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-04-01)

Corrigendum: Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-07-01)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01)

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
by: Mi Jeong Kwon, et al.
Published: (2019-07-01)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
by: Yogeshkumar Malam, et al.
Published: (2022-08-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
by: Berdunov V, et al.
Published: (2022-09-01)

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany
by: M.P. Lux, et al.
Published: (2022-01-01)

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
by: Ran Cheng, et al.
Published: (2020-10-01)

Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score
by: Abdalla Saad Abdalla Al-Zawi, et al.
Published: (2022-07-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
by: Berdunov V, et al.
Published: (2024-06-01)

Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score<sup>®</sup> Test?
by: Francesca Galati, et al.
Published: (2022-11-01)

Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients
by: Huang Z, et al.
Published: (2021-01-01)

Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease – a review of 137 cases
by: Abdalla Saad Abdalla Al-Zawi, et al.
Published: (2024-03-01)

Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
by: Alshamsan B, et al.
Published: (2021-12-01)

A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions
by: Asma Munir, et al.
Published: (2023-01-01)

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study
by: Arif Ali Awan, et al.
Published: (2024-02-01)

Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
by: Hongxiao Li, et al.
Published: (2022-06-01)

New Approaches in Breast Cancer Radiotherapy
by: Niyazi Volkan Demircan, et al.
Published: (2024-01-01)

The evolution of gene expression profiling in breast cancer – A narrative review
by: Banushree Chandrasekhar Srinivasamurthy
Published: (2023-01-01)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
by: Bernhard C. Pestalozzi, et al.
Published: (2017-04-01)

Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up
by: Cihan Uras, et al.
Published: (2022-11-01)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
by: Daniel A. Goldstein, et al.
Published: (2020-07-01)

MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
by: Ünal Ç, et al.
Published: (2023-09-01)

Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization
by: Çağlar Ünal, et al.
Published: (2023-10-01)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
by: Didi Feldman, et al.
Published: (2023-10-01)

The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer
by: Yael Bar, et al.
Published: (2024-10-01)

The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes
by: Jun Wang, et al.
Published: (2018-12-01)